Cardiovascular diseases are one of the leading causes of death in the United States, according to the Organisation for Economic Co-operation and Development. Although they can be prevented, cardiovascular diseases are not curable and account for nearly one-third of all deaths. Hence, the market for Adult and Pediatric Hemoconcentrators will experience high growth during the forecast period. The high prevalence of cardiovascular diseases in the region is also anticipated to boost the market growth.
According to the American Heart Association, 92.1 million adults in the U.S. suffer from cardiovascular diseases or aftereffects of stroke. This is the second-leading cause of death in the world, accounting for 836,546 deaths annually. In addition, major players in the market are involved in strategic mergers and acquisitions activities to increase their market share in the global market for Adult and Pediatric Hemoconcentrators. The WHO also noted that approximately 92.1 million adults are affected by the after-effects of cardiovascular disease. Moreover, the global total of cardiac diseases is estimated to reach 836,546 per year. As a result, the market for hemoconcentrators is set to expand into developing regions in the next few years. Despite this, the market for hemoconcentrators is likely to be boosted by several factors, including the risk of cardiovascular disease and the availability of highly developed healthcare infrastructure.
The device helps reduce blood clotting and keeps hematocrit levels stable during cardiac procedures. However, the COVID-19 epidemic and resulting halt in production and sales hampered the market's growth potential. Hemoconcentrators are used in cardiovascular surgery and the treatment of cancer and infectious diseases. The incidence of chronic diseases such as COVID and CHF is unlikely to decline over the next few years, so the market growth for these devices is expected to be high.
0 Comments